A detailed history of Jpmorgan Chase & CO transactions in Insmed Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,926,185 shares of INSM stock, worth $199 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
2,926,185
Previous 289,531 910.66%
Holding current value
$199 Million
Previous $7.85 Million 2396.23%
% of portfolio
0.02%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$22.0 - $69.71 $58 Million - $184 Million
2,636,654 Added 910.66%
2,926,185 $196 Million
Q1 2024

May 10, 2024

SELL
$25.72 - $29.94 $2.39 Million - $2.78 Million
-92,963 Reduced 24.3%
289,531 $7.85 Million
Q4 2023

Feb 12, 2024

SELL
$23.42 - $31.74 $596,530 - $808,449
-25,471 Reduced 6.24%
382,494 $11.9 Million
Q3 2023

Nov 14, 2023

BUY
$19.86 - $26.93 $931,573 - $1.26 Million
46,907 Added 12.99%
407,965 $10.3 Million
Q2 2023

Aug 11, 2023

BUY
$16.44 - $21.1 $1.12 Million - $1.44 Million
68,169 Added 23.27%
361,058 $7.62 Million
Q1 2023

May 18, 2023

BUY
$16.26 - $21.73 $2.76 Million - $3.69 Million
169,906 Added 138.15%
292,889 $4.99 Million
Q1 2023

May 11, 2023

SELL
$16.26 - $21.73 $4.34 Million - $5.8 Million
-267,016 Reduced 68.47%
122,983 $2.1 Million
Q4 2022

Feb 13, 2023

BUY
$16.98 - $23.15 $2.23 Million - $3.04 Million
131,475 Added 50.86%
389,999 $7.79 Million
Q3 2022

Nov 14, 2022

SELL
$20.88 - $28.21 $2.25 Million - $3.04 Million
-107,720 Reduced 29.41%
258,524 $5.57 Million
Q2 2022

Aug 11, 2022

BUY
$17.07 - $25.71 $4.35 Million - $6.54 Million
254,542 Added 227.88%
366,244 $7.22 Million
Q1 2022

May 11, 2022

BUY
$20.42 - $28.13 $322,105 - $443,722
15,774 Added 16.44%
111,702 $2.63 Million
Q4 2021

Feb 10, 2022

SELL
$25.89 - $33.45 $2.63 Million - $3.4 Million
-101,761 Reduced 51.48%
95,928 $2.61 Million
Q3 2021

Nov 12, 2021

BUY
$22.46 - $29.47 $4.44 Million - $5.83 Million
197,689 New
197,689 $5.44 Million

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $9.22B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.